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Mantle cell lymphoma (MCL) is a hematologic neoplasm characterised by the t(11;14)(q13;q32) 
translocation leading to aberrant cyclin D1 expression. The cell functions of cyclin D1 depend on its 
partners and/or subcellular distribution, resulting in different oncogenic properties. We observed the 
accumulation of cyclin D1 in the cytoplasm of a subset of MCL cell lines and primary cells. In primary 
cells, this cytoplasmic distribution was correlated with a more frequent blastoid phenotype. We 
performed immunoprecipitation assays and mass spectrometry on enriched cytosolic fractions from 
two cell lines. The cyclin D1 interactome was found to include several factors involved in adhesion, 
migration and invasion. We found that the accumulation of cyclin D1 in the cytoplasm was associated 
with higher levels of migration and invasiveness. We also showed that MCL cells with high cytoplasmic 
levels of cyclin D1 engrafted more rapidly into the bone marrow, spleen, and brain in immunodeficient 
mice. Both migration and invasion processes, both in vivo and in vitro, were counteracted by 
the exportin 1 inhibitor KPT-330, which retains cyclin D1 in the nucleus. Our data reveal a role of 
cytoplasmic cyclin D1 in the control of MCL cell migration and invasion, and as a true operator of MCL 
pathogenesis.
The CCND1 gene encoding cyclin D1 is the second most frequently amplified locus in solid cancers1. This gene 
is overexpressed in haematological cancers, due to t(11;14)(q13;q32) translocation, amplification of the CCND1 
gene, deletions or point mutations of the CCND1 3′-UTR, and even in the absence of any detectable genetic alter-
ation2. Consistent with the well-known role of cyclin D1 in regulating the cell cycle through cyclin-dependent 
kinase (CDK)4/6 activation, tumour cells with high levels of cyclin D1 have high proliferation rates, linked to 
a lower nutrient requirement. However, the oncogenic function of cyclin D1 is unlikely to be solely due to an 
increase in proliferation. Indeed, depending on its subcellular distribution (nuclear, cytoplasmic, at the outer 
mitochondrial membrane) and its partners (transcription factors, chromatin-modifying enzymes, cytosolic pro-
teins), cyclin D1 can regulate DNA damage response3,4, chromosome duplication and stability5,6, senescence7, 
mitochondrial function8,9 and migration10–12, all key biological processes for cancer initiation and maintenance.
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In mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin B-cell lymphoma, cyclin D1 is aber-
rantly expressed due to the t(11;14)(q13;q32) translocation, resulting in the localisation of this protein principally 
in the nucleus, where it controls tumour cell proliferation13. However, we observed a preferential accumulation of 
cyclin D1 in the cytosolic compartment in a subset of primary tumour samples and cell lines. The accumulation of 
cyclin D1 in the cytoplasm is associated with the aggressive blastoid variant of MCL. It remains unclear whether 
cyclin D1 has other oncogenic functions in addition to its role in controlling cell proliferation. We investigated 
the role of cytosolic cyclin D1 in MCL cells, by performing a proteomic screen for cyclin D1 partners. An analysis 
of the proteins interacting with cyclin D1 revealed that cyclin D1 bound factors were involved in cell migration, 
invasion and adhesion. We also found that cytoplasmic cyclin D1 was associated with higher levels of migration 
and invasion, in vitro and in vivo.
The migration and invasiveness of MCL cells can be reduced by treatment with KPT-330, a small inhibitor of 
nuclear export (SINE), which retains cyclin D1 in the nucleus. We suggest that SINEs could potentially be used as 
single agents or in combination with current drugs, as a promising therapeutic approach for invasive/metastatic 
MCL.
Results
Cyclin D1 accumulates in the cytoplasm in a subset of MCL lines and primary tumours. We ana-
lysed the subcellular distribution of cyclin D1 in MCL cells by immunofluorescence (IF), which revealed consid-
erable heterogeneity between cell lines. Cyclin D1 was found mostly in the nucleus and partly in the cytoplasm of 
JVM2, Granta-519 (hereafter referred to as Granta), and REC1 cells, but mostly in the cytoplasmic compartment 
of JeKo1 and Z138 cells (Fig. 1A). These distributions of cyclin D1 were checked by immunoblotting (IB) purified 
cytoplasmic/nuclear fractions and total extracts (Fig. 1B, upper panel and Fig. S1A). JeKo1 and Z138 cells had the 
highest cytoplasmic cyclin D1 contents, whereas this protein was found in both the cytoplasmic and nuclear com-
partments in REC1 cells. In the other cells, cyclin D1 was mostly present in the nucleus. We estimated the ratio of 
cytoplasmic to total cyclin D1 by densitometry (Fig. 1B, lower panel). We confirmed the preferential cytoplasmic 
localisation of cyclin D1 in JeKo1 and Z138 cells, in which this ratio exceeded 1. We then investigated whether 
such heterogeneity in subcellular distribution was observed in primary cells from MCL patients. IB revealed an 
accumulation of cyclin D1 in the cytoplasm of primary tumour cells in one (#6414) of three MCL patients tested 
(Fig. S1B). A retrospective immunohistochemistry (IHC) analysis on a cohort of 42 MCL patients followed at a 
single institution confirmed that staining for cyclin D1 defined two groups of patients: those with mostly nuclear 
Figure 1. Cyclin D1 may be preferentially distributed in the cytoplasm. (A) MCL cells were cytospun on 
glass slides, stained with an anti-cyclin D1 primary Ab and a goat Alexa Fluor® 488 conjugate anti-mouse 
IgG as secondary Ab, and counterstained with DAPI. The slides were analysed by confocal microscopy (x 180, 
magnification). (B) Upper panel, cultured MCL cells were harvested. Whole-cell and cytosolic extracts were 
obtained, subjected to SDS-PAGE and analysed by IB. The same blot was cut into strips and incubated with the 
indicated Abs. Anti-β-actin Ab was used as a loading control. An anti-PARP Ab was used to verify the purity of 
cytoplasmic extracts. Lower panel, IB experiments were carried out three times. Total and cytoplasmic cyclin 
D1 levels were estimated by densitometry (ChemiDoc XRS+, ImageLab software, Bio-Rad). The background 
of each image was subtracted from the bands of interest, then the density of each protein of interest was 
normalized against the density of control housekeeping β-actin protein. The ratio of cytoplasmic to total cyclin 
D1 level was calculated for each cell line for each gel. The mean values are reported in the table. (C) Cyclin D1 
staining of two biopsy specimens from MCL patients (x20, magnification).
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staining (e.g. patient #1) and those with both nuclear and cytoplasmic staining (e.g. patient #2, Fig. 1C). The pre-
dominance of a cytoplasmic pool cyclin D1 is, thus, not rare in MCL.
Cytoplasmic cyclin D1 is a marker of MCL aggressiveness. We investigated the clinical relevance of 
the subcellular localisation of cyclin D1, by analysing clinical and histological features at the time of initial diag-
nosis, in the same cohort of patients with MCL. Overall, 6/42 (14%) cases presented both nuclear and cytoplasmic 
immunostaining for cyclin D1, whereas 36/42 (86%) displayed immunostaining limited to the nucleus. Cyclin 
D1 expression was never found only in the cytoplasm. Patients with cytoplasmic immunostaining for cyclin D1 
were significantly more likely to have been diagnosed with the blastoid MCL variant14 (33% vs. 3%, p = 0.04). All 
these patients had a Ki-67 index of more than 10%, suggesting a more proliferative disease (Table 1). For example, 
patient #2 (Fig. 1C) was diagnosed with a blastoid variant on the basis of morphological criteria and had a Ki-67 
value of 66%. By contrast, the two groups did not differ significantly for the principal clinical features consid-
ered, such as splenomegaly, leukocytosis and bone marrow (BM) involvement (Table 1). The limited number of 
cases and the diverse treatments administered to the patients of this cohort precluded an analysis of overall and 
disease-free survival.
A proteomic-based interactome analysis reveals an extensive network of cyclin D1-interacting 
proteins. We investigated the main molecular functions of cytosolic cyclin D1 in MCL, by trying to identify 
factors interacting with cyclin D1 in JeKo1 cells. The partners of cyclin D1 may be common to different cyclin 
D1-expressing tumour cells4. We therefore included, for comparison, the U266 multiple myeloma (MM) cell line, 
in which CCND1 is activated by the insertion of an enhancer element15. In these cells, cyclin D1 is overexpressed 
and present in both in the nucleus and the cytoplasm9. Cytosol-enriched extracts were purified from both cell 
lines, subjected to immunoprecipitation with an anti-cyclin D1 antibody (Ab), and the cyclin D1-containing 
complexes obtained were subjected to mass spectrometry. Proteomic data revealed a large number of putative 
cyclin D1-interacting factors in each cell line (Tables S1 and S2) in addition to cyclin D1 itself. For validation of 
our protocol, we compared these two sets of proteins with available datasets for the Granta MCL cell line4. We 
identified 66 proteins strictly identical in the three cell lines, and 17 belonging to the same family. These pro-
teins were classified on the basis of their cellular functions, with the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) bioinformatics resources v6.7 (ref.16). In addition to well-known cell cycle regula-
tors (CDKs and CDKNs), cyclin D1 was found to interact with proteins involved in metabolism, transcriptional 
regulation, DNA repair, replication, protein folding, cell structure and organisation (Table S3). Some previously 
characterised partners of cyclin D1, such as PCNA, RAD51, HDAC and HSPs17,18, were also detected in our data-
set, validating our technical procedure.
The set of cytosolic partners of cyclin D1 is enriched in structural proteins. For identification of 
the most relevant cyclin D1-interacting factors in JeKo1 cells, we performed functional clustering with DAVID 
tools16 on the 200 proteins associated with cyclin D1 with the highest peptide coverage (Table S4). Interestingly, 
51 of these proteins were cytoskeleton-associated proteins (enrichment score: 13.16, p-value: 4.7 × 10−14). We 
then classified the same 200 proteins with the PANTHER™ system (v12.0, ref.19) on the basis of biological pro-
cess, molecular function and protein class. The results are presented as pie charts, with the percentage of proteins 
within some relevant fractions. These results confirmed the DAVID findings (Fig. 2A). The network obtained 
with STRING (v10.5, ref.20) summarised interactions between the previously characterised 51 proteins and cyc-
lin D1. This analysis predicted a functional enrichment for the actin-filament-based process (pathway ID: gene 
ontology (GO) 0030029), with a false discovery rate of 7.69 × 10−11 (Fig. 2B). Immunoprecipitation (IP) experi-
ments confirmed the binding of cyclin D1 to α-tubulin and β-actin proteins in JeKo1 cells (Fig. S1C), suggesting 
MCL patients
Cyclin D1 immunostaining
p
Nucleus
Nucleus/
cytoplasm
n = 36 n = 6
Clinical features
Median age (range) 68 (40–85) 54 (33–72) 0.101
Male (%) 18/35 (51%) 5/6 (83%) 0.20
Median MIPIa (range) 7.2 (4.8–10.7) 8.6 (5.3–10) 0.92
BM involvement 23/33 (69%) 3/6 (50%) 0.38
Stage IV (%) 28/33 (84%) 4/6 (66%) 0.29
Leukocytosis > 10 
Giga/L (%) 11/33 (33%) 3/6 (50%) 1
Splenomegaly (%) 11/33 (33%) 2/6 (33%) 1
Histological features
Ki-67 > 10% 22/36 (61%) 6/6 (100%) 0.15
Blastoid variant 1/36 (3%) 2/6 (33%) 0.048
Table 1. Correlation between clinical/histological features and cyclin D1 localization for MCL patients. aMIPI, 
mantle cell lymphoma international prognostic index. p was calculated in Fisher’s exact test. p < 0.05 was 
considered significant.
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a potential functional role of cyclin D1 in the control of actin fibre organisation and microtubule dynamics. B 
cells transduced to overexpress a TAT-cyclin D1 fusion protein9, displayed ultrastructural changes, such as a loss 
of protrusions (blebs) and a more regular cell surface (Fig. S1D), suggesting a link between cyclin D1 and cellular 
shape remodelling, which is crucial for the migratory/invasiveness phenotype.
Cytoplasmic cyclin D1 controls MCL migration and invasion, but not adhesion. Based on the 
potential role of cyclin D1 in regulating cellular shape through binding to structural proteins, we investigated the 
link between the processes of adhesion, migration and invasion, and cytoplasmic levels of cyclin D1.
The crosstalk between MCL cells and the stromal microenvironment in the BM and secondary lymphoid 
tissues plays an important role in the biology of the disease and is known to contribute to drug resistance21. In 
particular, MCL cells have high levels of adhesion molecules enabling them to interact with fibronectin and stro-
mal cells22. We therefore assessed the adhesion properties of MCL cells with fibronectin and HS-5 mesenchymal 
stromal cells. We found no correlation between cytosolic cyclin D1 level and the number of cells adhering to 
either fibronectin or HS-5 cells (Fig. S2A), ruling out a role for cytoplasmic cyclin D1 in MCL cell adhesion.
We assessed the ability of MCL cell lines to migrate over a gradient of stromal cell-derived factor 1 (SDF1), the 
relevant chemokine for MCL cells in chemotaxis assays23. JeKo1 and Z138 cells had a greater migratory capac-
ity than MCL lines in which cyclin D1 was located in the nucleus, and REC1 cells did not migrate (Fig. 3A). 
This greater migratory capacity was associated with greater filamentous (F-) actin polymerisation and a broader 
F-actin distribution, as shown by rhodamine-phalloidin staining before and after stimulation with SDF1 (Fig. 3B). 
In addition to playing a role in cell migration10–12,24, cyclin D1 has been associated with tumour invasiveness and 
metastasis25. Consistent with these findings, we observed that MCL cell lines with cytosolic cyclin D1 were more 
invasive in extracellular matrix (ECM)-coated invasion chambers and on an SDF1 gradient (Fig. 3C). These find-
ings are supported by the results of a recent study showing that a cytoplasmic and membrane-associated form of 
cyclin D1 controls the invasiveness of tumour cells26.
MCL cell lines have different engraftment kinetics in xenograft models. We then investigated 
the possible association of a cytoplasmic cyclin D1 distribution with greater invasiveness in MCL cells. We engi-
neered three cell lines from JeKo1, Z138 and REC1 cells for expressing the green fluorescence protein (GFP) or 
mCherry and the luciferase reporter gene (see details in the Supplementary Information). The three cell lines 
(JeKo1-mCherry-Luc, Z138-GFP-Luc and REC1-GFP-Luc) were injected into the tail vein of either SCID or 
NOD/SCID/IL2Rγnull (NSG) immunodeficient mice. Tumour growth was monitored weekly by bioluminescence 
imaging (BLI) after the i.p. injection of D-luciferin. Indeed, areas of luciferase activity are the sign of tumour 
growth. Based on sequential BLI measurements, tumours grew exponentially overtime, for the whole mouse as 
well as for individual luminescent foci (data not shown). The three cell lines invaded their pathophysiological 
Figure 2. Cytoskeleton-associated proteins interact with cyclin D1 in JeKo1 cells. The 200 proteins with the 
highest peptide coverage (Table S4) were analysed by DAVID Bioinformatics Resources v6.7 (ref.16). Relevant 
proteins were uploaded using their UniProt ID and organised into functional groups by the tool, according 
to GO terms. Among them, 51 were cytoskeleton-associated proteins (enrichment score: 13.16, p-value: 
4.7 × 10−14). (A) The same 200 proteins were next clustered with the PANTHER™ classification system v12.0 
according to their associated biological processes, molecular functions and protein classes (www.pantherdb.
org, ref.19). Results are presented as pie charts, with the percentage of proteins for some of the more relevant 
fractions. (B) The network designed with STRING (v10.5, www.string-db.org, ref.20) summarises associations 
between the 51 proteins previously characterised and cyclin D1. This analysis predicted functional enrichment 
in actin-filament-based processes (pathway ID: GO 0030029), with a false discovery rate of 7.69 × 10−11.
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niches, including the spleen and BM, and non-haematopoietic tissues, such as the brain and gut, with 100% 
penetrance (as shown in Fig. 4A and Table S5), thereby faithfully reproducing the features of MCL disease. 
Organ specimens showing luciferase activity contained tumour cells as assessed by flow cytometry analysis of 
GFP+/mCherry+ and CD20+/CD45+ cells (Fig. 4B). IHC on representative BM biopsy specimen confirmed 
the presence of cyclin D1+/CD20+ tumour cells. Representative tumour sections from the Jeko1 series showed 
an intense cytoplasmic cyclin D1 staining (Fig. 4C). Interestingly, marked differences were observed between 
the three cell lines in terms of lymphoid tissues-homing kinetics. Indeed, JeKo1 and Z138 cells had a higher 
engraftment capacity in NSG mice, and, to a lesser extent, SCID mice, than REC1 cells, and this engraftment 
also occurred earlier (Fig. 4D, Table S5). We thus conclude that the accumulation of cyclin D1 in the cytoplasmic 
compartment is associated with a higher invasion capacity in vivo.
The nuclear retention of cyclin D1 alters the invasiveness/migratory properties of MCL cells 
in vitro. Cyclin D1 is a cargo of XPO1, a major nuclear export protein27. We found that XPO1 was strongly 
expressed in both in the nuclear and cytosolic compartments of MCL cells, as expected from its function as a 
nuclear exportin (Fig. S2B). We treated JeKo1 cells with the SINE, KPT-330 and followed the redistribution of 
cyclin D1 over time. Cyclin D1 was strictly nuclear by 4 h after SINE treatment and remained nuclear 24 h later 
(Fig. 5A). The migratory capacities of JeKo1 and Z138 cells were analysed after a KPT-330-treatment. For both 
cell lines, significantly fewer cells migrated when cyclin D1 was retained into the nuclear compartment (Fig. 5B). 
Moreover, the blockade of cyclin D1 export from the nucleus led to a clear inhibition of F-actin polymerisa-
tion and changes in F-actin distribution (Fig. 5C). Similarly, both KPT-330 and leptomycin B (LMB), another 
SINE, decreased the invasiveness of these two cell lines (Fig. 5D). To further confirm these data, the JVM2 cell 
line that has low levels of cyclin D1 expression (Fig. 1B) was chosen as the recipient for transient transfections. 
Three kinds of plasmids were transfected by electroporation: p-EGFP encoding tGFP as a control, pD1a-EGFP 
encoding the canonical long form of cyclin D1 and pD1b-EGFP encoding a short isoform of cyclin D1. This short 
isoform lacks the Thr286 residue that is necessary for nuclear export by XPO1 and degradation by the ubiquitin/
proteasome system2. In turn, cyclin D1b accumulates in the nucleus. We assessed the capacity of transfected cells 
to migrate in the chemotaxis assay. As shown Fig. 5E, cyclin D1 expression increased the migration capacity of 
cells. However, this increased capacity is statistically higher for the long cyclin D1 isoform than the short nuclear 
isoform. Cytoplasmic cyclin D1 thus seems to be required to promote chemotaxis and MCL cell invasion in vitro.
Figure 3. Cytoplasmic cyclin D1 controls the invasion and migration of MCL cells in vitro. (A) MCL cells were 
used to seed the top chamber of Transwell inserts. The inserts were transferred into wells containing medium 
supplemented with SDF1 and the cells were allowed to migrate for 4 h. The cells present in the bottom well were 
then counted. Three independent inserts were used per experiment and each experiment was performed three 
times. The mean numbers of migrating cells ± s.d. are plotted on the graph. ***p < 0.001 in Student’s t-test. 
(B) MCL cells were left untreated (controls) or treated with SDF1 (200 ng/ml for 4 h), then cytospun, fixed and 
permeabilized. F-actin was visualised with rhodamine-stained phalloidin by confocal microscopy (Fluoview 
FV 1000 confocal microscope and Fluoview Viewer software, Olympus). Nuclei were counterstained with DAPI 
(x180, magnification). (C) Cultured MCL cells were used to seed the ECM-coated 5 μm-pore membranes of 
Transwell inserts, in the top chamber, containing serum-free medium. The inserts were then placed in wells 
containing SDF1 as a chemoattractant and incubated for 24 h. The cells invading the lower chamber were 
counted by flow cytometry. The means ± s.d. of three independent experiments with triplicate samples are 
indicated on the graph. ***p < 0.001 in Student’s t-test.
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 13946  | DOI:10.1038/s41598-017-14222-1
The nuclear relocalisation of cyclin D1 alters the invasiveness/migratory properties of MCL cells 
in vivo. For validation of the in vitro data, SCID mice (n = 5 per group) received intravenous injections of 
JeKo1-mCherry-Luc cells. They were then treated twice weekly with KPT-330 or vehicle and analysed by BLI once 
weekly (Fig. 6A). Tumour cells grew exponentially over time in both groups, but with a very different kinetics 
(Fig. 6B and C). Indeed, BLI results were positive in three of the five mice in the control group as soon as day 14 
after the injection of the cells, and all mice displayed luciferase activity at day 21, with a pattern consistent with 
BM infiltration (femur, tibia, rachis areas). By contrast, on day 21, luciferase activity was detected in only two of 
the five mice in the KPT-330-treated group, and the BLI signal was restricted to extramedullary organs, such as 
the brain and abdominal regions. Flow cytometry confirmed that spleen and BM biopsy specimens from animals 
treated with vehicle were enriched in CD20+/CD45+ tumour cells, whereas tumour cells were detected in the 
brains of only two mice and in the spleen of only one mouse treated with KPT-330 (Table 2). Accordingly, tumour 
cell infiltration into the BM was almost completely prevented in KPT-330-treated mice, as shown by IHC labelling 
for cyclin D1 and CD20 cells in representative biopsy specimens from both groups (Fig. 6D). Interestingly, in the 
few surviving CD20+ tumour cells, cyclin D1 accumulated in the nucleus (compare Fig. 6D and Fig. 3C). Thus, 
the nuclear retention of cyclin D1 delayed the onset of MCL cells engraftment, impaired tumour growth and 
altered tumour cells homing towards the lymphoid compartments. These in vivo data confirm the crucial role of 
the subcellular distribution of cyclin D1 In tumour cell engraftment and invasion.
Discussion
The CCND1 gene is the second most frequently amplified locus in the human genome1 and its product, the cyclin 
D1 protein, is overexproduced due to various genetic alterations, including translocations, mutations, oncogenic 
activation, and the deletion of miRNA-binding sites2. In association with CDK4/6, cyclin D1 controls the cell 
cycle and proliferation. Cyclin D1 is an oncogenic driver for several solid tumours and haematological malignan-
cies, but has also non-canonical oncogenic properties, as demonstrated by two previous proteomic screens4,28. 
We carried out a proteomic screen in a cyclin D1-expressing cell model, to characterise the partners of cyclin D1 
responsible for these non-canonical oncogenic features. A comparison of cyclin D1 interactomes in MCL cells 
(JeKo1 and Granta) and in MM cells (U266) revealed that cyclin D1 bound to factors involved in DNA repair 
(such as PCNA and RAD51), the heat shock response (HSPs, DNAJs), transcriptional regulation (HDACs), and 
Figure 4. MCL cells display variable engraftment properties. (A) We injected 107 MCL cells into the caudal 
veins of six-week-old SCID mice, and BLI analyses were performed, starting one week after cell injection. 
Mice receiving JeKo1-mCherry-Luc (J) or REC1-GFP-Luc (R) cells underwent imaging on the dorsal (D) and 
ventral (V) sides at successive time points. Images obtained 35 days after cell injection (at the time of death) 
are presented. (B) Cells were isolated from the BM and spleen and fluorescence signals were recorded by flow 
cytometry. The percentages of GFP+ or mCherry+ fluorescent cells on flow cytometry profiles are shown for R3, 
R7 and J7 mice. Isolated cells were also stained with anti-CD20-PE and anti-CD45-Vioblue Abs and analysed by 
flow cytometry. The numbers of CD20+ or CD45+ cells in the bone marrow of R3, R7 and J7 mice are indicated 
on the figure. (C) Haematoxylin/eosin staining (H&E) and IHC analyses of BM biopsy specimens from JeKo1-
inoculated mice showing the presence of CD20+ and cyclin D1+ human tumour cells (x200, magnification). (D) 
The percentages of SCID mice (left panel) and NSG mice (right panel) displaying luciferase activity as a function 
of time after injection are presented on Kaplan-Meyer curves drawn with Prism v6.0 software (GraphPad).
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to structural proteins. Most of these cyclin D1 partners in B-cell lymphoma and myeloma cells, are also present 
in solid tumours (breast cancer, squamous cell carcinoma and colorectal cancer)4, further validating our techni-
cal protocol. Our data confirm that non-canonical, CDK-dependent and -independent cyclin D1 functions are 
common to many cancer cells.
More importantly, our analysis of the most frequently identified partners of cyclin D1 in JeKo1 cells revealed 
a complex network of cytoskeleton-associated proteins. Using in vitro and in vivo devices, we identified an unex-
pected function of cyclin D1 in cell remodelling and in turn, migration and invasiveness. This finding is consistent 
with those of a recent study showing that a cytoplasmic form of cyclin D1 artificially attached to the cell mem-
brane controls invasiveness29. Cyclin D1/CDK4 complexes interact and phosphorylate the scaffold protein fila-
min A, a member of the actin-binding protein family, thereby controlling the invasion potential of breast cancer 
cells30. In prostate cancer cells, cytoplasmic cyclin D1/CDK4 complexes phosphorylate paxillin, a structural com-
ponent of focal adhesions29. Consistent with these findings, we found that the treatment of MCL cells with high 
levels of cytoplasmic cyclin D1 with the CDK4 inhibitor palbociclib reversed the invasive phenotype (Fig. S2C), 
suggesting that the kinase activity associated with cyclin D1 is required for MCL cell invasion. However, we found 
no evidences for the phosphorylation of paxillin, filamin A or cofilin, another actin-associated protein for which 
phosphorylation by cyclin D1/CDK4 complexes is involved in cell motility31 (data not shown). The downstream 
targets of cytoplasmic cyclin D1/CDK4 dimers regulating migration/invasion remains unknown, but our pro-
teomic data identify the characterized cytoskeleton-associated proteins as possible effectors.
Figure 5. The inhibition of cyclin D1 export impairs both the migration and invasion of MCL cells in vitro. 
(A) JeKo1 cells were treated with 300 nM KPT-330 and analysed by IF after 4 h or 24 h, to determine the 
distribution of cyclin D1. We used an anti-cyclin D1 as primary Ab and a goat Alexa Fluor® 488 conjugated 
anti-mouse IgG secondary Ab. Slides were counterstained with DAPI and analysed by confocal microscopy 
(x180, magnification). (B) JeKo1 and Z138 cells cells were treated with vehicle or KPT-330 (300 nM for 4 h) and 
then used to seed the upper chamber of Transwell inserts. The inserts were transferred to medium containing 
SDF1 and the cells were allowed to migrate for 4 h. The cells present in the bottom well were then counted. The 
data were normalised as a percentage of the control value. Three independent inserts were used per experiment 
and the experiment was performed three times. The mean numbers of migrating cells ± s.d. are plotted on the 
graph. ***p < 0.001 in Student’s t-tests. (C) F-actin staining with rhodamine-phalloidin was performed on 
JeKo1 and Z138 cells stimulated with 200 ng/ml SDF1 for 4 h alone or together with 300 nM KPT-330. Cells 
were counterstained with DAPI before examination (x 180, magnification). (D) JeKo1 and Z138 cells were 
treated with 5 ng/ml LMB, 300 nM KPT-330, or vehicle as a control for 4 h and then assayed for invasion, as 
described above. The data were normalized as a percentage of the control value. The experiment was carried out 
three times (LMB), or twice (KPT-330), with triplicate samples. **p < 0.01; ***p < 0.001 in Student’s t-tests. 
(E) JVM2 cells were transfected with either pEGFP, pD1a-EGFP or pD1b-EGFP expression plasmids using the 
Nucleofector II device (solution V, program A-023). After a 48 h-recovery period, the transfection efficiencies 
were estimated using the NucleoCounter NC-3000. Transfected cells were assayed for migration as described 
above. The experiment was performed twice with quadruplicate samples. The means ± s.d. are indicated on the 
graph, ***p < 0.001 in t-tests.
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KPT-185 and KPT-286, two XPO1 inhibitors, block the proliferation and induce the apoptosis of MCL cell 
lines and primary cells in vitro32,33. In vivo, the oral administration of KPT-276 also suppresses the growth of 
subcutaneous xenografts tumours32. We describe here the effect of KPT-330 in a mouse model reproducing 
the pathogenic features of human MCL. We found that KPT-330 impaired MCL cells engraftment and migra-
tion to the pathophysiologic niches of these cells. Consistent with our data, KPT-330 has been shown to inhibit 
SDF1-mediated signalling, preventing the migration of CLL cells34, and to restrict tumour spreading and the 
metastasis of prostate cancer cells by decreasing the secretion of metalloproteinases and urokinase35.
In KPT-330-treated mice, in addition to the lower engraftment potential of MCL cells, we found that the brain 
replaced the haematopoietic organs as the most frequently infiltrated organ. We interpret this finding as indicat-
ing that alterations occur to the factors required for MCL homing, such as chemokines, chemokine receptors, 
integrins, and sphingosine 1 phosphate receptors, after the relocalisation of cyclin D1 (and possibly other XPO1 
cargos) to the nucleus. Thus, tumour cells avoid haematopoietic organs because they cannot interact with their 
protective microenvironment. KPT-330 effects on the entry, retention and egress of MCL cells may be indirect 
and mediated by proteins such as cyclin D1, controlling motility and invasiveness.
Cyclin D1 has a heterogeneous subcellular distribution in MCL cell lines and primary tumour cells, but its 
presence in the cytoplasm does not mean that it is excluded from the nucleus. The nuclear functions of cyclin D1 
(essentially, regulation of the cell cycle and transcription) are therefore maintained in cells with a high cytoplas-
mic cyclin D1 content. The nuclear relocalisation of cyclin D1 associated with CDK4 has been recognised as a 
mechanism for controlling proliferation in solid tumours24,25,30. Our data, therefore, strongly suggest that tumour 
cells proliferation may be controlled by nuclear cyclin D1, whereas tumour cells invasiveness may be controlled 
by the cytoplasmic fraction of the protein. Consistent with this conclusion, Fusté and colleagues reported that the 
attachment of cyclin D1 at the cytoplasmic membrane of tumour cells had no effect on proliferation but increased 
tumour invasion and metastasis29.
Further studies are required, but our finding of different oncogenic properties associated with different sub-
cellular distributions of cyclin D1 at diagnosis in MCL patients could up new possibilities for personalised treat-
ment. In particular, the combination of KPT-330 or next-generation SINEs with currently available proteasome 
inhibitors, such as bortezomib or carfilzomib, might decrease the aggressiveness of MCL tumour cells, limiting 
their spread. The maintenance of malignant cells outside of their niches would leave these cells more accessible 
to chemotherapy.
Figure 6. The inhibition of cyclin D1 export impairs MCL engraftment in vivo. (A) We injected 107 mCherry-
Luc-JeKo1 cells i.v. into six-week-old male SCID mice (n = 10). Mice were randomised to two groups (n = 5). 
One group received KPT-330 (10 mg/kg) orally twice weekly, whereas the other group received vehicle i.p. Both 
treatments began on the day of cell injection and BLI analyses began one week later. Mice were imaged on the 
dorsal and ventral sides once weekly after the i.p injection of D-luciferin. Images of individual mice (1–5) from 
both groups (KPT-330 and vehicle) are presented. Mice were killed after the last BLI images were obtained 
(day 35). (B) The graph shows the Tukey boxplots for individual BLI data as a function of time after cell 
injection for the two groups. (C) At the end of the experiment, the blood, spleen, lower limbs and brain of each 
mouse were collected and tumour cells were analysed by IHC. Staining for cyclin D1 and CD20 on BM biopsy 
specimens of one mouse per group are shown. Enlarged boxes: representative cyclin D1 nuclear staining (x800, 
magnification).
www.nature.com/scientificreports/
9Scientific RepoRts | 7: 13946  | DOI:10.1038/s41598-017-14222-1
Methods
Antibodies. Antibodies (Abs) against cyclin D1 (sc-718), β-actin (sc-4778), PARP (poly(ADP-ribose) poly-
merase, sc-8007) and exportin 1 (XPO1, sc-5595) were purchased from Santa Cruz Biotechnology. An Ab against 
α-tubulin (T6199) was purchased from Sigma-Aldrich, and an anti-glyceraldehyde-3-phosphate dehydrogenase 
Ab (GAPDH, clone 6C5) was obtained from Life Technologies. Abs against hexokinase 2 (#2106), and binding 
immunoglobulin protein (BiP, #3183) were obtained from Cell Signaling Technologies. ImmunoPure peroxi-
dase-conjugated goat anti-rabbit and anti-mouse IgG (H + L) secondary Abs were purchased from Pierce Protein 
Research Products.
Mouse Organ % of CD20+ cells % of CD45+ cells
C1
Brain <1 <1
BM 33 34
Spleen 61 64
Blood 3 nda
C2
Brain <1 <1
BM 22 21
Spleen 62 65
Blood 11 nd
C3
Brain 2 2
BM 53 60
Spleen 78 79
Blood 5 nd
C4
Brain 2 1
BM 62 63
Spleen 78 79
Blood 4 nd
C5
Brain 7 4
BM 11 10
Spleen nd nd
Blood <1 1.0
K1
Brain 0 0
BM <1 <1
Spleen 3 <1
Blood <1 <1
K2
Brain 1 1
BM <1 <1
Spleen <1 <1
Blood <1 <1
K3
Brain 2 3
BM <1 <1
Spleen <1 <1
Blood <1 <1
K4
Brain <1 <1
BM <1 <1
Spleen <1 <1
Blood <1 <1
K5
Brain 5 6
BM <1 <1
Spleen <1 <1
Blood <1 <1
Table 2. Percentage of tumour cells in various organs from control (C1-5) and KPT-330 treated (K1-5) 
SCID mice. JeKo1-mCherry-Luc cells were injected into the caudal vein of 10 SCID mice, which were then 
randomised into two groups: a control group (C series) and a group receiving KPT-330 (K series). K1-5 mice 
were treated orally, twice weekly, with 1 mg/kg KPT-330. The overall distribution of MCL tumor cells was 
determined by BLI during the time course of the experiment and analysed by flow cytometry at the time of 
mouse death (day 35 after cells injection for all mice except C5, which was killed on day 28). Cells were isolated 
from the organs indicated and stained with CD20-PE or CD45-VioBlue Abs. The percentage of stained cells was 
deduced from the cytometry profiles analyzed with the Kaluza software v1.5 A. and, not determined.
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MCL patients and analysis of cyclin D1 localization. We assessed the clinical relevance of the subcel-
lular distribution of cyclin D1 protein, by retrospectively analysing cyclin D1 immunostaining patterns by IHC 
(anti-cyclin D1 Ab, EP12, Dako) of specimen from a cohort of 42 cyclin D1+ MCL cases followed at a single insti-
tution and reported in a previous study36. The clinical and histological features of cases were compared according 
to their cyclin D1 staining patterns (nuclear vs. nuclear + cytoplasmic) were compared (Table 1).
Cells culture and transfection. The MCL cell lines have been described elsewhere37. CM cells, used as a 
control, are immortalised and untransformed mature B cells. Cell lines were maintained in culture in RPMI 1640 
medium (Lonza) supplemented with 10–20% foetal calf serum (PAA Laboratories), 2 mM L-glutamine and anti-
biotics (Lonza), under a humid atmosphere at 37 °C. Cell authentication was based on short tandem repeat (STR) 
profiling (IdentiCell, Aarhus, Denmark).
The pEGFP-N1 plasmid was purchased from Clontech Laboratories Inc., and the pD1a-EGFP and 
pD1b-EGFP38 plasmids were kindly provided by D.A. Solomon (USCF, San Francisco, CA). Both were sequenced 
to check the integrity of the coding sequence. Plasmids were amplified and purified (QIAGEN Plasmid Midi 
Kit). JVM2 cells (7 × 106 cells) were cultured without antibiotics for 24 h. Cells were resuspended in 100 μl 
of Nucleofector Solution V (Lonza) containing 2 μg of purified plasmids. JVM2 cells were transfected with a 
Nucleofector II device (Lonza) using the A-023 program. After transfection, cells were transferred to culture 
plates in complete culture medium and assayed for migration 48 h later as described below. At that time, the 
transfection efficiency (recorded by the number of GFP+ cells) was verified using the NucleoCounter TM-3000 
according to the recommendations of the supplier (Chemometec).
Transwell migration and invasion assays. Cultured MCL cells (5 × 105 cells per insert) were suspended 
in RPMI 1640 medium containing 0.5% bovine serum albumin (BSA) and used to seed the top chamber of 
Transwell inserts (Millicell Hanging Cell Culture Inserts 5 μm PET, Millipore). The inserts were transferred to 
wells containing RPMI 1640 medium supplemented with recombinant SDF1 (200 ng/ml, R&D Systems) as a 
chemoattractant, as previously described23. As a control for assay specificity, SDF1-free medium was added to 
the lower chamber. Plates were then incubated for 4 h at 37 °C, and cells migrating to the lower chambers were 
counted by flow cytometry. The accuracy of cell counting was checked by adding fluorescent particles to the 
chambers (Accucount fluorescent particles, SpheroTech).
For invasion assays, 5 × 105 cells in serum-free medium plus 0.5% BSA were added to the top cham-
ber of 24-well inserts (Costar Transwell Permeable Support, pore size 5 μm) coated with ECM obtained from 
Engelbrecht-Holm-Swarm mouse sarcoma (Sigma-Aldrich). Medium supplemented with SDF1 (200 ng/ml) or 
without supplementation (for control), was added to the bottom chamber. Plates were incubated for 24 h at 37 °C. 
The invading cells present in the lower chambers were counted by flow cytometry.
LMB (L2913) was purchased from Sigma-Aldrich, and KPT-330 (S7232) from SelleckChem. For migration 
and invasion assays, cells were treated with either 5 ng/ml LMB or 300 nM KPT-330 for 4 h before their addition 
to the Transwell inserts.
Indirect immunofluorescence, F-actin staining and confocal microscopy analysis. MCL cells 
were cytospun, fixed in 4% paraformaldehyde and permeabilized in 0.5% Triton-X100. The slides were then 
stained with an anti-cyclin D1 Ab (sc-718, Santa Cruz Biotechnology), and then with Alexa Fluor 633-conjugated 
goat anti-rabbit IgG (in green) and counterstained with DAPI (4′,6-diamidino-2-phenylindole dihydrochloride, 
Molecular Probes, in blue). Slides were observed with a confocal fluorescence microscope (Fluoview FV 100, 
Olympus). For XPO1 inhibition, cells were treated with KPT-330 for 4 h before IF analysis.
Cultured cells were either left untreated or treated with 200 ng/ml SDF1 to stimulate chemotaxis. Fixed and 
permeabilized cells were incubated with rhodamine-phalloidin, as recommended by the supplier (Molecular 
Probes) and analysed by fluorescence microscopy. In some experiments, SDF1-treated cells were also treated with 
300 nM KPT-330 (or vehicle) for 4 h before F-actin staining.
Immunoprecipitation and immunoblotting. Whole-cell protein extracts were prepared from cultured 
cells with the M-PER Mammalian Protein Extraction Reagent (Pierce Biotechnology) according to the man-
ufacturer’s instructions. Fractions enriched in cytosol were prepared with a lysis buffer containing 1% NP40, 
20 mM Tris pH 7.6, 120 mM NaCl, 1 mM EDTA and a cocktail of protease inhibitors (cOmplete ULTRA tablets, 
Roche). Cytoplasmic and nuclear extracts were prepared with the Nuclear/Cytosol Fractionation Kit (BioVision). 
Extract purity was checked by IB with Abs directed against the strictly nuclear PARP protein, and the endoplas-
mic reticulum-bound BiP protein. The methods used for IB and IP have been described in details elsewhere37.
Affinity purification, mass spectrometry, protein characterization. These methods are described 
in details in the Supplementary Information.
Engraftment of GFP/mCherry-Luc expressing MCL cells in immunocompromised mice. In 
vivo experiments were conducted in accordance with the recommendations of the EEC (86/609/CEE). They 
were approved by the Ethics Committee for Animal Experimentation of our institutions (Comité Normandie 
d’éthique en matière d’expérimentation animale (CENOMEXA) agreement N109-11-12/32/11-15 in France 
and Hospital Clínic Ethics Committee (IRB, reg.num. 2012/7498) in Spain). Z138-GFP-Luc, REC1-GFP-Luc, 
JeKo1-mCherry-Luc cell lines were generated by infection with lentivirus or retrovirus vectors (see 
Supplementary Information). Male SCID (n = 5–7 per group) and NSG (n = 6 per group) mice (age 6–8 weeks) 
received an i.v. injection of 107 cells in a final volume of 100 μl. Tumour engraftment was assessed weekly by 
BLI. Mice received an i.p. injection of 75 mg/kg of D-luciferin and were then examined with a PhotonIMAGER 
(Biospace lab) for 5 min. Ventral plus dorsal emissions were captured through the whole mouse body. When the 
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mice were killed, their infiltrated organs were collected. Single-cell suspensions were prepared and stained with 
IOTest CD20-PE (phycoerythrin, IM1451, FL2) or anti-CD45-VioBlue (clone 5B1, Miltenyi Biotech., FL9) Abs, 
or with the corresponding isotype controls. Cells were also directly analysed for GFP or mCherry fluorescence 
by flow cytometry. In addition, BM biopsy specimens were fixed in 4% formalin and embedded in paraffin for 
IHC analyses according to previously published procedures37. Human tumour B-cell detection procedures were 
performed on consecutive tissue sections, with anti-cyclin D1 (EP12) and anti-CD20 (L26) primary Abs (Dako). 
Preparations were examined under an Olympus DP70 microscope equipped with of a 40/0.75 NA objective and 
DPManager software v2.1.1 (Olympus).
For analysis of the effects of KPT-330 on cell engraftment, SCID mice (n = 10) received i.v. injections of 
JeKo1-mCherry-Luc cells as described above. On the day of the injection, the mice were assigned to two groups 
receiving either orally a 10 mg/kg dose KPT-330 or i.p. an equal volume of vehicle twice weekly. Mice underwent 
BLI once per week, beginning one week after cell injection. When the mice were killed, their infiltrated organs 
were removed and processed for flow cytometry and IHC analyses.
Statistical analyses. The Student’s t-test was used to determine the significance of differences between 
two experimental groups. Data were analysed in two-tailed tests, with p < 0.05 (*) considered to be significant. 
Fisher’s exact test was used to evaluate the distribution of the various histological and clinical parameters between 
MCL cases as a function of cyclin D1 immunostaining pattern.
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